Comparing tirzepatide and semaglutide for obesity and metabolic syndrome
Compares tirzepatide and semaglutide, with lifestyle changes, in adults with obesity.
Plain-language title generated from the registry record
Registry title: Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs
Key facts
- Where
- Taipei, TaiwanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 65 years old?
Source: NCT07589322, who can take part
Where in Taiwan
- Tri-Service General HospitalTaipei, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tri-Service General Hospital (TSGH)
- Trial code
- NCT07589322
- Record updated
- 15 May 2026
- Original description
This randomized, open label, head to head clinical trial directly compares tirzepatide and semaglutide in adults with obesity and metabolic syndrome (N=120, age 20-65, 1:1 randomization). Participants undergo deep phenotyping at baseline, 6 months, and 12 months, including DXA (regional fat, lean mass, and BMD), MRI PDFF (liver fat), 7 site skinfold thickness, grip strength, fasting biochemistry, and AI processed 12 lead ECGs. Centralized biobanking of serum, plasma, and PBMCs enables targeted and discovery multi omic analyses.Read full original descriptionShow less
Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study
This randomized, open label, head to head clinical trial directly compares tirzepatide and semaglutide in adults with obesity and metabolic syndrome (N=120, age 20-65, 1:1 randomization). Participants undergo deep phenotyping at baseline, 6 months, and 12 months, including DXA (regional fat, lean mass, and BMD), MRI PDFF (liver fat), 7 site skinfold thickness, grip strength, fasting biochemistry, and AI processed 12 lead ECGs. Centralized biobanking of serum, plasma, and PBMCs enables targeted and discovery multi omic analyses.
Inclusion: Age 20-65 years; BMI ≥27 kg/m² with metabolic syndrome (ATP III or IDF criteria); Stable background medications (antihypertensives, statins, etc.) for ≥3 months; Able and willing to provide informed consent and comply with study procedures.
Exclusion: Current use of GLP 1RA, tirzepatide, or other incretin based therapies within 3 months; Contraindications to MRI or DXA (e.g., metal implants incompatible with MRI, pregnancy); History of diabetes; history of pancreatitis; personal/family history of medullary thyroid carcinoma or MEN2; Recent (<3 months) acute coronary syndrome, stroke, or coronary revascularization; eGFR <30 mL/min/1.73 m², decompensated liver disease, NYHA class III-IV heart failure.